Skip to content

US · GUTS · BIOTECHNOLOGY

Fractyl Health, Inc. (GUTS) intrinsic value and stock valuation

$0.82as of 2026-11-21 · Mkt cap 49.45M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Fractyl Health, Inc. DCF and intrinsic value

InvestorsCraft values GUTS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GUTS’s statements →

Fractyl Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Burlington, MA 01803 fractyl.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-140.95M
20192025
Free cash flow
-$-90.89M
20192025
Total equity
$9.46M-8.7% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$90K$120K$0.00$0.00
Operating income-$-96.82M-$-93.53M-$-50.84M-$-49.38M-$-36.93M
Net income-$-140.95M-$-68.69M-$-77.09M-$-46.45M-$-38.73M
EPSd-$-1.86M-$-1.58M-$-1.62M-$-975.64K-$-813.48K
Operating cash flow-$-90.33M-$-65.52M-$-42.82M-$-46.24M-$-33.46M
Capital expenditure-$-560K-$-1.76M-$-360K-$-60K-$-50K
Free cash flow-$-90.89M-$-67.29M-$-43.18M-$-46.3M-$-33.51M
Total assets$121.4M$108.1M$76.2M$61M$102.6M
Total debt$61.7M$62.5M$373.7M$306.8M$304.3M
Net debt-$-19.89M-$-4.96M$340.2M$257.5M$208.9M
Total equity$9.46M$28.4M-$-325.06M-$-252.32M-$-209.32M
Cash and short-term investments$81.5M$67.5M$33.5M$49.3M$95.5M
Income statement
20252024202320222021
Revenue$0.00$90K$120K$0.00$0.00
Cost of revenue$0.00$50K$80K$450K$0.00
Gross profit$0.00$40K$40K-$-450K$0.00
Research and development expenses$74.5M$70.5M$38M$34.4M$26.4M
Selling, general and administrative expenses$22.3M$0.00$0.00$14.6M$10.5M
Other expenses$0.00$23.1M$12.8M$0.00$0.00
Operating expenses$96.8M$93.6M$50.9M$48.9M$36.9M
Cost and expenses$96.8M$93.6M$51M$49.4M$36.9M
Interest income$1.54M$4.15M$1.26M$800K$0.00
Interest expense$0.00$0.00$0.00$0.00$1.44M
Depreciation and amortization$1.13M$680K$290K$450K$680K
Ebitda-$-139.82M-$-68.02M-$-76.81M-$-46M-$-36.62M
Operating income-$-96.82M-$-93.53M-$-50.84M-$-49.38M-$-36.93M
Total other income/expenses, net-$-44.14M$24.8M-$-26.25M$2.93M-$-1.81M
Income before tax-$-140.95M-$-68.69M-$-77.09M-$-46.45M-$-38.73M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-140.95M-$-68.69M-$-77.09M-$-46.45M-$-38.73M
Weighted average shares outstanding$75.8M$43.5M$47.6M$47.6M$47.6M
Weighted average diluted shares outstanding$75.8M$43.5M$47.6M$47.6M$47.6M
Balance sheet
20252024202320222021
Cash and short-term investments$81.5M$67.5M$33.5M$49.3M$95.5M
Net receivables$0.00$0.00$20K$0.00$0.00
Inventory$0.00$70K$70K$0.00$0.00
Total current assets$87.6M$71.8M$35.7M$51.6M$96.4M
Property, plant and equipment, net$29.2M$31.4M$30.8M$1.65M$1.34M
Goodwill and intangible assets$0.00$0.00$830K$860K$0.00
Long-term investments$4.25M$4.25M$4.25M$4.25M$0.00
Total non-current assets$33.8M$36.3M$40.6M$9.33M$6.16M
Total assets$121.4M$108.1M$76.2M$61M$102.6M
Accounts payable$1.57M$3.24M$550K$980K$970K
Short-term debt$5.1M$4.96M$2.73M$1.25M$16.7M
Deferred revenue$0.00$0.00$0.00-$-980K-$-970K
Total current liabilities$18.3M$19.8M$11.2M$7.31M$23.7M
Long-term debt$56.5M$57.5M$371M$305.6M$287.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$93.6M$59.9M$390.1M$306M$288.2M
Capital lease obligations$26M$32.3M$28.5M$1.72M$1.28M
Total liabilities$111.9M$79.7M$401.3M$313.3M$311.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-556.26M-$-415.31M-$-346.62M-$-269.52M-$-223.07M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$9.46M$28.4M-$-325.06M-$-252.32M-$-209.32M
Total investments$4.25M$4.25M$4.25M$4.25M$0.00
Total debt$61.7M$62.5M$373.7M$306.8M$304.3M
Net debt-$-19.89M-$-4.96M$340.2M$257.5M$208.9M
Cash flow statement
20252024202320222021
Net income-$-140.95M-$-68.69M-$-77.09M-$-46.45M-$-38.73M
Depreciation and amortization$1.13M$680K$290K$450K$680K
Stock-based compensation$6.68M$14.4M$4.3M$3.14M$2.09M
Change in working capital-$-400K$9.59M$990K-$-1.24M$1.71M
Accounts receivable$0.00$20K-$-20K$0.00$0.00
Inventory$70K$0.00-$-70K$0.00$0.00
Accounts payable-$-1.67M$2.69M-$-430K$0.00$670K
Net cash provided by operating activities-$-90.33M-$-65.52M-$-42.82M-$-46.24M-$-33.46M
Investments in property, plant and equipment-$-560K-$-1.76M-$-360K-$-60K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-560K-$-1.76M-$-360K-$-60K-$-50K
Common stock issued$105.4M$103.7M$0.00$320K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$105M$101.2M$27.4M$4.35M$99.9M
Net change in cash$14.1M$33.9M-$-15.74M-$-46.2M$66.4M
Cash at end of period$85.8M$71.7M$37.8M$49.3M$95.5M
Operating cash flow-$-90.33M-$-65.52M-$-42.82M-$-46.24M-$-33.46M
Capital expenditure-$-560K-$-1.76M-$-360K-$-60K-$-50K
Free cash flow-$-90.89M-$-67.29M-$-43.18M-$-46.3M-$-33.51M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Fractyl Health, Inc.

        Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

        CEO
        Harith Rajagopalan
        Employees
        100
        Beta
        2.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Fractyl Health, Inc. (GUTS)?

        InvestorsCraft does not currently publish an intrinsic value for GUTS. How the IC value is calculated.

        Is GUTS undervalued?

        InvestorsCraft does not publish an undervaluation signal for GUTS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.